Evidence map›Paper›PMID 33048842›Full record

ArticleJCI insight2020

Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.

Camila H Coelho, Steven T Nadakal, Patricia Gonzales Hurtado, Robert Morrison, Jacob D Galson, Jillian Neal, Yimin Wu, C Richter King, Virginia Price, Kazutoyo Miura and 14 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 4 countries.

Camila H CoelhoLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Steven T NadakalLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Patricia Gonzales HurtadoLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Robert MorrisonLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Jacob D GalsonUniversity Children's Hospital Zurich, Zurich, Switzerland.
Jillian NealLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Yimin WuPATH's Malaria Vaccine Initiative, Washington, DC, USA.
C Richter KingPATH's Malaria Vaccine Initiative, Washington, DC, USA.
Virginia PricePATH's Malaria Vaccine Initiative, Washington, DC, USA.
Kazutoyo MiuraLaboratory of Malaria and Vector and Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, USA.
Sharon Wong-MaddenLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Justin Yai Alamou DoritchamouLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
David L NarumLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Nicholas J MacDonaldLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Maryonne Snow-SmithLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Marissa VignaliLaboratory of Malaria and Vector and Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, USA.
Justin J TaylorFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Marie-Paule LefrancIMGT, the International ImMunoGeneTics Information System, Laboratoire d'ImmunoGénétique Moléculaire, Institut de Génétique Humaine, UMR9002 CNRS, Université de Montpellier, Montpellier, France.
Johannes TrückUniversity Children's Hospital Zurich, Zurich, Switzerland.
Carole A LongLaboratory of Malaria and Vector and Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, USA.
Sara A Healy
Issaka SagaraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies, Bamako, Mali.
Michal FriedLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
National Institute of Allergy and Infectious Diseases · USU.S. President's Malaria Initiative · USUniversity Children's Hospital Zurich · CHAdaptive Biotechnologies (United States) · USCentre National de la Recherche Scientifique · FRFred Hutch Cancer Center · USUniversité des Sciences, des Techniques et des Technologies de Bamako · ML

Funding

Vaccines to Interrupt Malaria Transmission: Clinical DevelopmentZIAAI001009 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2025
$84.8M
Intramural NIH HHS ZIA AI001009
6 · The paper itself

Abstract

Plasma antimalarial Ab can mediate antiparasite immunity but has not previously been characterized at the molecular level. Here, we develop an innovative strategy to characterize humoral responses by integrating profiles of plasma immunoglobulins (IGs) or Abs with those expressed on B cells as part of the B cell receptor. We applied this strategy to define plasma IG and to determine variable (V) gene usage after vaccination with the Plasmodium falciparum zygote antigen Pfs25. Using proteomic tools coupled with bulk immunosequencing data, we determined human antigen-binding fragment [F(ab')2] peptide sequences from plasma IG of adults who received 4 doses of Pfs25-EPA/Alhydrogel. Specifically, Pfs25 antigen-specific F(ab')2 peptides (Pfs25-IG) were aligned to cDNA sequences of IG heavy (IGH) chain complementarity determining region 3 from a data set generated by total peripheral B cell immunosequencing of the entire vaccinated population. IGHV4 was the most commonly identified IGHV subgroup of Pfs25-IG, a pattern that was corroborated by V heavy/V light chain sequencing of Pfs25-specific single B cells from 5 vaccinees and by matching plasma Pfs25-IG peptides and V-(D)-J sequences of Pfs25-specific single B cells from the same donor. Among 13 recombinant human mAbs generated from IG sequences of Pfs25-specific single B cells, a single IGHV4 mAb displayed strong neutralizing activity, reducing the number of P. falciparum oocysts in infected mosquitoes by more than 80% at 100 μg/mL. Our approach characterizes the human plasma Ab repertoire in response to the Pfs25-EPA/Alhydrogel vaccine and will be useful for studying circulating Abs in response to other vaccines as well as those induced during infections or autoimmune disorders.

Indexed as

Adjuvants, ImmunologicAdolescentAdultAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanAntimalarialsB-LymphocytesClinical Trials as TopicFemaleHumansImmunoglobulinsMalaria, FalciparumMalaria VaccinesMaleMiddle AgedAdjuvants, ImmunologicAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanAntimalarialsImmunoglobulinsMalaria VaccinesPfs25 protein, Plasmodium falciparumProtozoan ProteinsAdaptive immunityImmunologyMalariaVaccines

Identifiers

PMID33048842
PMCPMC7710313
OpenAlexW3092450590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.